Related Experiment Videos
Five-year change in statistical designs of phase II trials published in leading cancer journals
S Thezenas1, J Duffour, S Culine
1Department of Biostatistics, Val d'Aurelle Regional Cancer Center, Parc Euromédecine, 208, rue des Apothicaires, 34298 Montpellier cedex 05, France. sthezenas@valdorel.fnclcc.fr
Abstract:
This study compares the evolution in statistical design reporting for phase II cancer clinical trials published in the six following leading journals: American Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, Cancer, European Journal of Cancer and Journal of Clinical Oncology. Only articles where tumour response was considered as the primary endpoint were selected. A total of 393 phase II trials published in 1995 (n=185) and 2000 (n=208) were reviewed. Neither sample size nor design parameters were specified in 157 (85%) and 113 (46%) papers in 1995 and 2000, respectively. 28 (15%) and 95 (46%) papers included at least some information on the statistical designs used: Gehan (4.3% and 3.3%), Fleming (2.2% and 4.3%), and Simon (2.7% and 11.0%). Ad hoc, non-referenced methods were used in 5.9% and 27.3% articles in 1995 and 2000, respectively. Although there is an increase in the mention of at least some statistical design parameters in phase II cancer clinical trials over a 5-year period in these selected cancer journals, the use of referenced methods is still short or often inadequate.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Dosage Regimens: Designs and Approaches
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...